TR201900670T4 - İnhalasyon için yöntem ve formülasyon. - Google Patents
İnhalasyon için yöntem ve formülasyon. Download PDFInfo
- Publication number
- TR201900670T4 TR201900670T4 TR2019/00670T TR201900670T TR201900670T4 TR 201900670 T4 TR201900670 T4 TR 201900670T4 TR 2019/00670 T TR2019/00670 T TR 2019/00670T TR 201900670 T TR201900670 T TR 201900670T TR 201900670 T4 TR201900670 T4 TR 201900670T4
- Authority
- TR
- Turkey
- Prior art keywords
- inhalation
- formulation
- methods
- relates
- delivery
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
Bu buluş ilaç aktarımıyla ve özellikle inhalasyon için kuru tozlar formunda biyolojik olarak aktif ajanların aktarılmasıyla ilgilidir. Buluş ayrıca, bu tip kuru toz formülasyonlarının hazırlanması için yöntemlerle ve bunların kullanılması için yöntemlerle de ilgilidir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011903049A AU2011903049A0 (en) | 2011-08-01 | Method and formulation for inhalation |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201900670T4 true TR201900670T4 (tr) | 2019-02-21 |
Family
ID=47628537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/00670T TR201900670T4 (tr) | 2011-08-01 | 2011-11-07 | İnhalasyon için yöntem ve formülasyon. |
Country Status (20)
Country | Link |
---|---|
US (3) | US20140294969A1 (tr) |
EP (1) | EP2739268B1 (tr) |
CN (1) | CN103841960B (tr) |
AU (1) | AU2011374218B2 (tr) |
BR (1) | BR112014002646B1 (tr) |
CA (1) | CA2879317C (tr) |
CY (1) | CY1121373T1 (tr) |
DK (1) | DK2739268T3 (tr) |
ES (1) | ES2708218T3 (tr) |
HR (1) | HRP20190080T1 (tr) |
HU (1) | HUE041858T2 (tr) |
LT (1) | LT2739268T (tr) |
MX (1) | MX355833B (tr) |
PL (1) | PL2739268T3 (tr) |
PT (1) | PT2739268T (tr) |
RS (1) | RS58456B1 (tr) |
SI (1) | SI2739268T1 (tr) |
TR (1) | TR201900670T4 (tr) |
WO (1) | WO2013016754A1 (tr) |
ZA (1) | ZA201401526B (tr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1494732T1 (sl) | 2002-03-20 | 2008-08-31 | Mannking Corp | Inhalacijski aparat |
JP5078014B2 (ja) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | ジケトピペラジン合成の触媒反応 |
HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
EP1928423B1 (en) | 2005-09-14 | 2015-12-09 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
EP1986679B1 (en) | 2006-02-22 | 2017-10-25 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
KR101558026B1 (ko) | 2008-06-13 | 2015-10-06 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
CA2728523C (en) | 2008-06-20 | 2020-03-10 | Mannkind Corporation | An interactive apparatus and method for real-time profiling of inhalation efforts |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
CA2801936C (en) | 2010-06-21 | 2021-06-01 | Mannkind Corporation | Dry powder drug delivery system and methods |
KR101940832B1 (ko) | 2011-04-01 | 2019-01-21 | 맨카인드 코포레이션 | 의약 카트리지용 블리스터 패키지 |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
CA2879317C (en) * | 2011-08-01 | 2019-01-15 | Monash University | Method and formulation for inhalation |
EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
CA2878457C (en) | 2012-07-12 | 2021-01-19 | Mannkind Corporation | Dry powder drug delivery systems and methods |
BR122019026637B1 (pt) * | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
WO2015175961A1 (en) * | 2014-05-16 | 2015-11-19 | Stc.Unm | Vaccination compositions, methods of making, and methods of use |
WO2016067252A1 (en) | 2014-10-31 | 2016-05-06 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
WO2017044601A1 (en) * | 2015-09-11 | 2017-03-16 | Abbott Laboratories | Powdered nutritional product containing branched-chain amino acids and a sugar alcohol |
US9585835B1 (en) * | 2015-09-16 | 2017-03-07 | Sansa Corporation (Barbados) Inc. | Inhalable nicotine formulations and methods of making and using the same |
PT108885B (pt) * | 2015-10-12 | 2019-02-13 | Hovione Farm S A | Método de produção de partículas compósitas inaláveis mediante a utilização de um atomizador de três fluidos |
EP3532500A1 (en) | 2016-10-31 | 2019-09-04 | Vectura Limited | Inhalable powder composition comprising il-13 antibody |
MX2019010263A (es) * | 2017-03-07 | 2019-10-09 | Philip Morris Products Sa | Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas. |
CN111202722A (zh) * | 2020-02-13 | 2020-05-29 | 江苏艾立康药业股份有限公司 | 一种洛匹那韦吸入干粉药物组合物及其制备方法 |
CN111202723A (zh) * | 2020-02-15 | 2020-05-29 | 江苏艾立康药业股份有限公司 | 一种达芦那韦吸入干粉药物组合物及其制备方法 |
CN111202724A (zh) * | 2020-02-16 | 2020-05-29 | 江苏艾立康药业股份有限公司 | 一种阿比朵尔吸入干粉药物组合物及其制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6258341B1 (en) * | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
US6749835B1 (en) * | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
US6894026B1 (en) * | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
EG24184A (en) * | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
GB0304540D0 (en) * | 2003-02-27 | 2003-04-02 | Elan Drug Delivery Ltd | Particle formulation and its preparation |
CA2555841A1 (en) * | 2004-02-12 | 2005-09-01 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
WO2007014391A2 (en) * | 2005-07-27 | 2007-02-01 | Nastech Pharmaceutical Company Inc. | Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents |
GB0525254D0 (en) * | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
WO2007095288A2 (en) * | 2006-02-13 | 2007-08-23 | Nektar Therapeutics | Methionine-containing protein or peptide compositions and methods of making and using |
CA2701719A1 (en) * | 2007-10-05 | 2009-04-09 | President And Fellows Of Harvard College | Dry powders of cellular material |
WO2009143011A1 (en) * | 2008-05-20 | 2009-11-26 | Novartis Ag | Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
CN101669925B (zh) * | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
EP2344200A2 (en) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
CA2879317C (en) * | 2011-08-01 | 2019-01-15 | Monash University | Method and formulation for inhalation |
-
2011
- 2011-11-07 CA CA2879317A patent/CA2879317C/en active Active
- 2011-11-07 ES ES11870462T patent/ES2708218T3/es active Active
- 2011-11-07 CN CN201180073937.6A patent/CN103841960B/zh active Active
- 2011-11-07 WO PCT/AU2011/001430 patent/WO2013016754A1/en active Application Filing
- 2011-11-07 EP EP11870462.6A patent/EP2739268B1/en active Active
- 2011-11-07 LT LTEP11870462.6T patent/LT2739268T/lt unknown
- 2011-11-07 HU HUE11870462A patent/HUE041858T2/hu unknown
- 2011-11-07 PL PL11870462T patent/PL2739268T3/pl unknown
- 2011-11-07 AU AU2011374218A patent/AU2011374218B2/en active Active
- 2011-11-07 SI SI201131657T patent/SI2739268T1/sl unknown
- 2011-11-07 MX MX2014001345A patent/MX355833B/es active IP Right Grant
- 2011-11-07 PT PT11870462T patent/PT2739268T/pt unknown
- 2011-11-07 RS RS20190066A patent/RS58456B1/sr unknown
- 2011-11-07 BR BR112014002646-7A patent/BR112014002646B1/pt active IP Right Grant
- 2011-11-07 US US14/236,465 patent/US20140294969A1/en not_active Abandoned
- 2011-11-07 TR TR2019/00670T patent/TR201900670T4/tr unknown
- 2011-11-07 DK DK11870462.6T patent/DK2739268T3/en active
-
2014
- 2014-02-27 ZA ZA2014/01526A patent/ZA201401526B/en unknown
-
2016
- 2016-11-04 US US15/343,408 patent/US11065297B2/en active Active
-
2019
- 2019-01-14 HR HRP20190080TT patent/HRP20190080T1/hr unknown
- 2019-01-18 CY CY20191100070T patent/CY1121373T1/el unknown
-
2021
- 2021-06-15 US US17/348,023 patent/US20220152145A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2879317A1 (en) | 2013-02-07 |
AU2011374218B2 (en) | 2017-05-11 |
CN103841960B (zh) | 2017-07-07 |
CA2879317C (en) | 2019-01-15 |
ES2708218T3 (es) | 2019-04-09 |
US20140294969A1 (en) | 2014-10-02 |
HUE041858T2 (hu) | 2019-05-28 |
US20220152145A1 (en) | 2022-05-19 |
DK2739268T3 (en) | 2019-02-25 |
BR112014002646B1 (pt) | 2021-09-14 |
WO2013016754A1 (en) | 2013-02-07 |
EP2739268A4 (en) | 2015-03-25 |
RS58456B1 (sr) | 2019-04-30 |
EP2739268B1 (en) | 2018-10-31 |
BR112014002646A8 (pt) | 2017-06-20 |
US20170224762A1 (en) | 2017-08-10 |
MX2014001345A (es) | 2014-11-13 |
CY1121373T1 (el) | 2020-05-29 |
SI2739268T1 (sl) | 2019-05-31 |
CN103841960A (zh) | 2014-06-04 |
HRP20190080T1 (hr) | 2019-03-22 |
US11065297B2 (en) | 2021-07-20 |
AU2011374218A1 (en) | 2014-03-20 |
ZA201401526B (en) | 2017-09-27 |
BR112014002646A2 (pt) | 2017-06-13 |
EP2739268A1 (en) | 2014-06-11 |
LT2739268T (lt) | 2019-03-25 |
MX355833B (es) | 2018-05-02 |
PL2739268T3 (pl) | 2019-07-31 |
PT2739268T (pt) | 2019-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201900670T4 (tr) | İnhalasyon için yöntem ve formülasyon. | |
CY1119192T1 (el) | Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα | |
PH12014502778A1 (en) | Antibody formulation | |
CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
EA201390203A1 (ru) | Способы получения тубулизинов | |
MX348823B (es) | Formulaciones estables de linaclotida. | |
PH12015502593A1 (en) | COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS | |
EA201301264A1 (ru) | Способ получения неорганического материала в виде частиц | |
MX2021009377A (es) | Formulaciones de espuma y aparatos para su suministro. | |
MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
MX2014002780A (es) | Composiciones farmaceuticas que comprenden un inhibidor de aromatasa. | |
PH12014502834A1 (en) | Pharmaceutical form for extended release of active substances | |
MY183106A (en) | Fine dry particulate retinoid active agent compostions and topical formulations including the same | |
MX339243B (es) | Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos. | |
EA201491845A1 (ru) | Получение стерильных активных фармацевтических ингредиентов | |
MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
WO2013170086A3 (en) | Formulations for the delivery of active ingredients | |
CY1119871T1 (el) | Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων | |
MX357704B (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
MX2014015199A (es) | Formulacion de pexiganan estable. | |
BR112013025610A2 (pt) | uso de um metapneumovírus aviário vivo, e, composição farmacêutica | |
EP3010534A4 (en) | Pharmaceutical formulations and methods for oral delivery of biologically active ingredient | |
LV15003A (lv) | Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei | |
TR201203087A2 (tr) | Seftibüten ve klavulanik asit formülasyonları. | |
TN2013000104A1 (en) | Formulations for bovine granulocyte colony stimulating factor and variants thereof |